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Introduction
Proteomic profiling offers the opportunity to identify proteins that 
mediate apoptotic pathways, when cells are treated with cytotoxic agents 
[1]. Proteomic results have the potential to provide new insight into the 
molecular mechanisms of this group of molecules at the cellular level 
[2]. More than 99% of currently approved clinical drugs are organic 
compounds. In contrast, the percentage of metal-containing drugs 
(metallodrugs) is very low [3]. In cancer chemotherapy, however, 
platinum coordination compounds are essential agents, with proven 
efficacy against a variety of tumors. The discovery of the anticancer 
properties of cisplatin (cis-dichloro diammineplatinum (II), cis-
[PtIICl2(NH3)2] has triggered the development of several other metal-
based compounds [4]. Because of the established clinical applications 
of these platinum-based drugs, the number of research initiatives to 
identify other metallodrugs that can be used in cancer therapy has 
increased. The use of transition metal compounds other than platinum 
has also attracted attention, to improve the therapeutic effects and 
to overcome the disadvantages of current platinum-based drugs [5]. 
Various metal complexes (e.g., Pt, Au, and Ru) are currently evaluated, 
either clinically or experimentally, as therapeutic agents in treatment of 
malignant diseases, including several cancer types. 
Gold coordination complexes, for instance, demonstrate 
outstanding cytotoxic properties, and certain ruthenium complexes 
possess a remarkable ability to inhibit metastases of solid invasive 
tumors. Previous studies showed that cytotoxic gold(III) compounds 
are able to induce cell death through apoptosis [6,7]; essentially triggered 
through a direct mitochondrial damage [8]. Within this frame, the 
pivotal role of thioredoxin reductase as a probable target for cytotoxic 
gold compounds was highlighted [9]. Among currently investigated 
anticancer metallodrugs, a few ruthenium- compounds hold great 
promise as experimental antimetastatic agents [10,11]. Interestingly, 
their relevant antimetastatic actions are usually associated to weak 
cytotoxicity, and to acceptable profiles of systemic toxicity that render 
them very suitable for further drug development and for clinical use 
[12]. For instance, imidazolium trans-[tetrachloro(DMSO)(imidazole) 
ruthenate(III)] NAMI-A was found to reduce dramatically the number 
and the size of metastases in certain in vivo models of cancer, e.g. the 
Lewis lung carcinoma, and is currently undergoing phase II clinical 
trials [13]. Similarly, the ruthenium(II) organometallic complex 
[Ru(η6-toluene)Cl2(PTA)] (where PTA=1,3,5-triaza-7-phospha-
tricyclo-[3.3.1.1] decane) named RAPTA-T is weakly cytotoxic in 
vitro, while showing favorable antimetastatic effects in vivo [14], as 
well as remarkable anti-angiogenic properties [15]. The mode of action 
of antimetastatic ruthenium compounds remains elusive and largely 
unexplored. For these reasons, a proteomic approach was utilized 
for investigating the mode of action of these anticancer metallodrugs 
[16,17].
In previous papers, we reported lists of proteins found to be 
differentially expressed in the human ovarian cancer cisplatin-sensitive 
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cell line (A2780/S), after treatment with four different cytotoxic 
gold compounds, namely: Auranofin [2], Auoxo6 [2], AuL12 [1] 
and Au2Phen [1]. In a very recent paper, we have used for the first 
time, 2D-DIGE to investigate the mode of action of two anticancer 
ruthenium compounds, namely NAMI-A and RAPTA-T in A2780/S 
human cancer cells [18]. Changes in the expression of intracellular 
proteins after the treatment at non-cytotoxic concentrations were 
monitored. 
In this paper, we carry out a detailed bioinformatic analysis on 
proteins identified in those previous proteomic studies, including the 
protein-protein interaction network, in order to better understand 
the biological processes involved in metallodrugs treatment, and 
find possible common features in the mechanism of action of these 
compounds. To interpret all the protein lists obtained in our previous 
proteomics results, with the two classes of metallodrugs, we used 
a BioProfiling.de [19] tool: PPI spider [20] freely available on the 
analytical web portal (http://www.BioProfiling.de/gene_list). In one 
submission, the protein/gene list can be analyzed by a collection of 
tools. The input list is translated into a network model, according to 
the topology of the two web-based tools. We provide models of protein 
interactions that represent the most probable scenario of how proteins 
identified within the list are connected, in order to identify a possible 
combination of metallodrugs in experimental chemotherapy of cancer 
disease, to increase the effectiveness of metallodrugs treatment. The 
expression of many of these proteins resulted affected by most of the 
gold compounds used, and this strengthens the validity of the results. 
Methods
Bioinformatic analysis
BioProfiling.de: BioProfiling.de provides a comprehensive 
analytical toolkit for the interpretation of protein lists. Asinput, 
BioProfiling.de accepts a protein list. As output, in one submission, the 
gene list is analyzed by a collection of tools, which employs advanced 
enrichment or network-based statistical frameworks. BioProfiling.de 
provides a common interface for the collection of recently developed 
tools [19]; description and details of the tools can be found in original 
publications [20]. The gene list is profiled with respect to the most 
information available regarding gene function, protein interactions, 
pathway relationships, in silico predicted microRNA to gene 
associations, as well as, information collected by text mining. The web 
portal is freely available at http://www.BioProfiling.de/gene_list.
To better understand the key regulated biological processes 
occurring after metallodrugs A2780/S cells treatment, bioinformatics 
analysis to the differentially expressed list of proteins identified by 
our previous quantitative proteomic studies, were carried out. The 
network analysis used has been freely available web-based tool for the 
interpretation of experimentally derived protein lists in the context of 
a global PPI network. A dataset containing the standard gene symbols 
of the identified proteins was uploaded. The significantly enriched PPI 
networks have been determined with the default parameter settings.
Statistical methodology: PPI Spider implements a statistical 
framework for the interpretation of protein lists in the context of a 
global PPI network. The statistical significance of the inferred model 
is estimated based on the distribution of the model size for a random 
protein list. Statistical significance of the model is computed by a 
Monte Carlo simulation procedure [19,20]. 
Network visualization using Cytoscape: Cytoscape (http://
www.cytoscape.org/) is a software platform for visualizing molecular 
interaction networks and integrating these interactions with gene 
expression profiles. Cytoscape supports several algorithms for the 
layout of networks [21].
Results
Bioinformatic analysis of proteomic data
To gain a deeper insight into the mechanism of action of selected 
anticancer Gold and Ruthenium compounds, and establish whether 
these metallodrugs have common protein targets, we performed a 
bio-informatic analysis on the lists of proteins previously identified 
by proteomic studies. We have used the web-based tool BioProfiling.
de, which provides a common interface for the collection of recently 
developed tools; description and details of the tools can be found in the 
original publications [20]. 
We used proteins previously identified, showing variation in 
expression level following treatment with AuL12, Au2Phen, Auoxo6, 
Auranofin and with NAMI-A and RAPTA-T in a cisplatin-sensitive 
human ovarian cancer cell line (A2780/S). 
To start the analysis, we uploaded a text file with the 34 proteins, 
and we selected Homo sapiens as organism. We put in the same 
analysis all the proteins, listed in Table 1, whose expression resulted 
modified after the two different treatments. The expression of many 
of these proteins resulted affected by most of the gold compounds 
used, and this strengthens the validity of the results. The table reported 
in Figure 1 summarizes the results for this submission using the PPI 
Spider. In the table, it is also shown the models’ definition, which 
specifies the maximal allowed distance between two input proteins 
connected (D0 means directly connected, D1 one intermediate is 
allowed, D2 two intermediate are allowed), the number of input 
proteins covered by the system, and the corresponding significance of 
the best inferred model. As it is evident the inferred network model 
D2 covers 22 proteins of the 34 used as input. The p-value estimated 
for this model is statistically significant (p-value less than 0.005). We 
decided to analyze this network, and in Figure 1 is reported, a graphical 
illustration of the protein-protein interaction network created by PPI 
Spider and obtained by Cytoscape: http://www.cytoscape.org/, the 
software platform for visualizing the results. Four proteins belong to 
the Ruthenium molecules treatments (circle in the Figure 1), and 18 
proteins to the Gold metallodrugs. This network includes intermediate 
proteins not previously detected in our proteomic studies, reported 
in Table 2, and represented as triangles in the network of Figure 1. 
These intermediate proteins could be potentially interesting targets 
for metallodrugs, even if their expression level could not be directly 
influenced by the treatment.
Among them, the software found few proteins correlated with anti-
proliferation, and/or apoptosis. To group the proteins present in the 
PPI network, we divided them in two classes: Class A including proteins 
involved in apoptosis, cellular proliferation and DNA stability, and 
Class B that includes proteins responsible of cytoskeleton dynamics, 
splicing regulation and protein biosynthesis. 
The two classes are reported in Figure 1: 
a) Class A–Apoptosis, cellular proliferation and DNA stability: 
Important nodes of this Group are represented by two intermediate 
proteins: the TNF receptor-associated factor 1 (TRAF1–Q13077), an 
adapter molecule that plays a role in the regulation of cell survival and 
Citation: Gamberi T, Magherini F, Bini L, Messori L, Gabbiani C, et al. (2013) New Insights into the Molecular Mechanisms of Selected Anticancer 
Metal Compounds through Bioinformatic Analysis of Proteomic Data. J Proteomics Bioinform S6: 006. doi:10.4172/jpb.S6-006
Page 3 of 6
Microarray ProteomicsJ Proteomics Bioinform ISSN:0974-276X JPB, an open access journal 
Accession 
numbera Protein name Top Function
Gold Ruthenium
P07437 Tubulin beta chain constituent of microtubules. Guidi et al. [1]
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic 2 acetyl-CoA = CoA + acetoacetyl-CoA. Guidi et al. [18]
P60174 Triosephosphate isomerase associated with cardiomyopathy and increased susceptibility to infection. Magherini et al. [2]
P55209 Nucleosome assembly protein 1-like 1 chromatin formation and regulation of proliferation. Guidi et al. [1]
P29692 Elongation factor 1-delta Protein synthesis Guidi et al. [18]
P23919 Thymidylate kinase Pyrimidine metabolism Guidi et al. [1] Guidi et al. [18]
P49773 Histidine triad nucleotide-binding prot 1 Hydrolyzes adenosine 5'-monophosphoramidate substrates
Guidi et al. [1]
Magherini et al. [2] Guidi et al. [18]
Q9Y3F4 Ser-thr kinase receptor-associated protein spliceosomal snRNP assembly Guidi et al. [1]
Q9NQR4 Omega-amidase NIT2 omega-amidase activity Guidi et al. [1] Guidi et al. [18]
P30041 Peroxiredoxin-6 redox regulation of the cell. Magherini et al. [2]
P62253 Ubiquitin-conjugation enzyme E2 G1 Protein modification Guidi et al. [18]
P31943 Heterog nuclear ribonucleoprot H ribonucleoprotein complexes. Magherini et al. [2]
P09429 High mobility group protein B1 DNA binding proteins that associates with chromatin and bend DNA. Magherini et al. [2]
Q9NRF9 DNA pol epsilon sub 3 nucleosome-remodeling activity Guidi et al. [18]
P62258 14-3-3 protein epsilon Adapter protein binds to a large number of partners. Guidi et al. [1]
P63104 14-3-3 protein zeta/delta Adapter protein implicated in the regulation of signaling pathways. Guidi et al. [1]
P12004 Proliferating cell nuclear antigenCICLIN
This protein is an auxiliary protein of DNA polymerase 
delta Guidi et al. [1]
P07339 Cathepsin D active in intracellular protein breakdown. Guidi et al. [18]
P62937 Peptidyl-prolyl cis-trans isomerase ACyclophilin A
accelerate the folding of proteins. Guidi et al. [1]
P61978 Heterog nuclear ribonucleoprot K pre-mRNA-binding proteins. Guidi et al. [1]
P15311 EZRINA connections of major cytoskeletal structures. Magherini et al. [2]
Q06830 Peroxiredoxin 1 redox regulation of the cell Magherini et al. [2] Guidi et al. [18]
Q9UMX0 Ubiquilin 1 Interacts with the proteasome 19S subunit Guidi et al. [1]
P14174 Macrophage migration inhibitory factor Pro-inflammatory cytokine Guidi et al. [1]
P60709 Actin, cytoplasmic 1 involved in various types of cell motility. Guidi et al. [1]
Q14257 Reticulocalbin-2 Binds calcium. Guidi et al. [1]
P24534 Elongation factor 1-beta Protein synthesis Guidi et al. [1]
P61758 Prefoldin subunit 3 Binds specifically to cytosolic chaperonin Guidi et al. [18]
P26447 Protein S100-A4 calcium-binding protein Guidi et al. [18]
P28838 Cytosol aminopeptidase involved in the processing turnover of intracellular proteins Guidi et al. [1]
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Functions in mitochondrial tRNA maturation. Magherini et al. [2]
P33316 Deoxiuridine 5’ triphosphate nucleotidohydrolase, mit involved in nucleotide metabolism Guidi et al. [18]
Q969Q6 Serine/Treonine-protein phosphatase 2A play a role in the activation-induced cell death Guidi et al. [18]
Q08752 Peptidyl-prolyl cis-trans isomerase D accelerates the folding of proteins Guidi et al. [18]
Table 1: Experimentally identified proteins list used as input in PPI Spider analysis.
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apoptosis [22], and the Transcription factor Sp1 (SP1–P08047). This 
protein can activate or repress transcription in response to physiological 
and pathological stimuli, and regulates the expression of a large number 
of genes involved in apoptosis, differentiation and immune responses 
[23]; moreover, it plays a role in the cellular response to DNA damage. 
Among the proteins of Class A, we found the previously identified 
Reticulocalbin-2 (Q14257) [1], belonging to the CREC protein family, 
including promising biomarkers in a variety of diseases [24]. We found 
other proteins strictly correlated with the DNA damage and DNA 
assembly, and identified in previous proteomics experiments. Among 
them, the apoptotic marker NALP1 (Nucleosome assembly protein 1 
P55209) [1], connected with the two previously discussed intermediate 
nodes: the adapter molecule TRAF1 and the transcription factor Sp1. 
An intermediate node mapped in this network and involved in DNA 
repair mechanisms [25] is the variant histone H2A (H2AFX–P16104), 
which replaces conventional H2A histon in a subset of nucleosomes 
[26]. 
b) Class B–Cytoskeleton dynamics, splicing regulation and 
protein biosynthesis:  In this class are included many proteins present 
as intermediate nodes and involved in cytoskeleton organization, like 
the protein Cofilin1 (CFL–P23528), important for the regulation of 
actin cytoskeleton dynamics, and for the progression through mitosis 
[27]. It is connected to the cytoplasmic βactin (P60709), identified by 
proteomics experiments [1], that is a component of the cytoskeleton 
and a mediator of internal cell motility. Among this group, we found 
another intermediate node, an actin-related protein involved in 
cytoskeleton organization [28] (ACTR6–Q9GZN1). The protein SMN2 
(Q16637) is a node between two input proteins involved in splicing: 
the Heterogeneous nuclear ribonucleoprotein H (P31943) [2], and the 
Serine-threonine kinase receptor-associated protein (Q9Y3F4) [1]. The 
SMN2 protein plays an essential role in spliceosomal assembly, and 
is required for pre-mRNA splicing [29]. Moreover, an intermediate 
node which connects the two elongation factors, previously identified 
by proteome analysis (Elongation factor 1-beta - P24534 [1] and 
Elongation factor 1-delta - P29692 [18], is the Elongation factor 1-alpha 
2 (EEF1A2–Q05639). These components of the eEF1 complex have 
the canonical functions in translation elongation [30], and many non-
canonical functions, including roles in nuclear export events, turnover 
of misfolded proteins, binding and bundling of the actin cytoskeleton 
and apoptosis. Moreover, the cellular senescence has been found 
associated with changes of eEF1 levels in colon and lung cancer cell 
lines [31]. The A and B classes of proteins are connected together by 
an intermediate node: Receptor-like protein kinase1 (RIPK1–Q13546) 
a Serine-threonine kinase, which transduces inflammatory and cell-
death signals (necroptosis) and DNA damage [32]. 
Enriched network analysis 
The new list of proteins, obtained by the PPI Spider analysis 
described above, and including: the proteins previously identified 
by proteomics experiments and reported in Table 1, and the nodes 
corresponding to new intermediate proteins and inferred by the PPI 
spider analysis, has been used as input list for an enriched second 
PPI analysis. This new list of proteins was used, in order to identify 
a new network model to provide new insight into possible biological 
mechanisms of metallodrugs. The table of Figure 2 shows the results 
obtained with this new submission: the inferred network model D1 
covers 40 proteins from the 52 used as input, and with the model D2 
are covered 42 proteins. Both the models show a statistical significance 
with a p<0.005. Since the proteins connected in the model D1 belong 
to the input list, and there are not missing proteins in this model, we 
decided to analyze the model D2 to find new information about new 
intermediate proteins (nodes), correlated with the input list. In Figure 
2 is represented the graphical illustration of the D2 model obtained 
by Cytoscape, and modified by the authors. In this sub-network are 
present two intermediate proteins (triangles in the Figure 2): the 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH-P04406), and 
the Cleavage stimulation factor subunit 2 (CSTF2-P33240). In our 
network, we found GAPDH connected with the Peroxiredoxin-1 (Q 
06830) [2,18], identified by previous proteomic analysis, which is 
involved in redox regulation of the cell. Recently, Maller et al. [33], 
found that GAPDH’s oxidation state controls the protein biosynthesis, 
and its nitrosylation state is important to induce apoptosis. Moreover, 
Figure 1: (Upper side) Table of results obtained by PPI Spider analysis after 
the submission of the previously identified proteins list and (lower side) network 
inference model D2 visualization obtained by Cytoscape. See text for details.
Figure 2: (Upper side) Table of results of the network obtained by PPI Spider 
analysis after the submission of the enriched proteins list and (lower side) 
network inference model D2 visualization obtained by Cytoscape. See text for 
details.
Citation: Gamberi T, Magherini F, Bini L, Messori L, Gabbiani C, et al. (2013) New Insights into the Molecular Mechanisms of Selected Anticancer 
Metal Compounds through Bioinformatic Analysis of Proteomic Data. J Proteomics Bioinform S6: 006. doi:10.4172/jpb.S6-006
Page 5 of 6
Microarray ProteomicsJ Proteomics Bioinform ISSN:0974-276X JPB, an open access journal 
they propose its potential peroxidase activity and the decomposition of 
H2O2 by GAPDH is already acknowledged. In this network, GAPDH 
is also connected with REL (Q04864) component of the NF-kappa-B 
p65-c-Rel complex, which plays a role in the regulation of apoptosis 
[34]. CSTF2 is one of the multiple factors required for polyadenylation 
and 3’-end cleavage of mammalian pre-mRNAs. This subunit is directly 
involved in the binding to pre-mRNAs. Aragaki  et al. [35], found 
that there is a significant correlation of CSTF2 expression, with poor 
prognosis for patients with lung cancers. CSTF2 could play important 
roles in cell proliferation and invasion.
Discussion
The goal of this work was to elucidate whether the list of proteins 
previously identified by proteomics analysis, could perform biological 
interactions. Many biological functions are carried out by the 
integrated activity of interacting proteins. We aimed to build a single, 
representative network that possibly grouped together all the proteins 
differentially expressed, and reported in all previously published papers 
from our laboratory. It is hypothesized that proteins interact through 
specific interactions and a web tool, which employs a network-based 
statistical framework for the interpretation of protein lists has been 
used in this work. We used the global PPI Spider network, using all 
the previously identified proteins as input. In order to reduce the 
probability of false positives, most of the proteins used as input, have 
been previously validated by western blot analyses. Moreover, the 
expression of many of these proteins resulted affected by most of the 
gold compounds used, and this strengthens the validity of the results. 
After this first analysis, we obtained a new list of proteins, including the 
intermediate nodes, new proteins representing common interactors, 
as predicted by PPI Spider. We reload this “enriched” new list for a 
further PPI analysis. Comparing all the results, we noticed that the 
functions of some proteins could be correlated. The first correlation is 
between two proteins that are involved in RNA processing. The second 
correlation we found was between two proteins involved in connections 
of cytoskeletal components to membrane: the protein Ubiquilin-1 and 
the protein Ezrin. In our recent paper, we reported that two ruthenium 
compounds caused proteomic alterations, and we found that 9 proteins 
are in common between RAPTA-T and NAMI-A, implying that their 
respective mechanisms are highly correlated [18]. Analysis of all these 
proteins by PPI Spider resulted a significant network model, indicating 
two classes of proteins correlated to each other and belonging to: i) 
Apoptosis, cellular proliferation and DNA stability, and ii) Cytoskeleton 
dynamics, splicing regulation and protein biosynthesis. Among these 
two groups, we found some intermediate proteins able to connect most 
of the proteins in the input list. A new protein-protein interaction 
analysis, using the enriched new input list resulted in a second network 
model, showing as intermediate nodes two proteins involved in cellular 
redox regulation and dynamics RNA stability, suggesting a common 
mechanism of action for the metallodrugs studied. These proteins may 
be further investigated as possible drug targets, and more extensive 
bioinformatics analyses will be carried out to better identify and 
characterize the cellular perturbations induced by these substances. 
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